



July 12, 2023

**BSE Limited**

Department of Corporate Services,  
P. J. Towers,  
Dalal Street,  
**MUMBAI - 400 001.**

**National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051**

**Dear Sir/Madam,**

**Re: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').**

**Subject: U.S. FDA Inspection of the Company's Nagpur Oral Solid Dosage Facility.**

We would like to inform that U.S. FDA inspected Lupin's Nagpur Oral Solid Dosage Facility from July 3 to July 11, 2023. The inspection closed with issuance of a Form-483 with two observations.

We are confident of addressing the observations raised, and will work with the U.S. FDA to resolve them at the earliest. We uphold quality and compliance issues with utmost importance and remain committed to be compliant with CGMP quality standards across all our facilities.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

**For LUPIN LIMITED**

**R. V. SATAM  
COMPANY SECRETARY  
(ACS - 11973)**